Evolent Health, Inc (NYSE:EVH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Shares of Evolent Health carry a consensus rating of "Moderate Buy" from 17 analysts (13 buys, 3 holds, 1 sell) with an average 1‑year price target of $6.04.
• Several brokers have trimmed targets recently—as low as $5 (UBS) and $6 (Oppenheimer)—reflecting reduced near‑term expectations despite many buy/outperform designations.
• Large institutions (Durable Capital, Rubicon, Eventide, Goldman) have initiated or increased positions while the stock trades at $2.51 (market cap ≈ $280M); the company posted a slight EPS beat but revenue fell 27.5% YoY and net margin remains negative.

Shares of Evolent Health, Inc (NYSE:EVH - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seventeen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $6.0385.

Several analysts recently issued reports on EVH shares. KeyCorp cut Evolent Health from an "overweight" rating to a "sector weight" rating in a research report on Wednesday, February 25th. Citizens Jmp cut their target price on Evolent Health from $11.00 to $10.00 and set a "market outperform" rating for the company in a research report on Tuesday, January 6th. UBS Group cut their target price on Evolent Health from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. Oppenheimer cut their target price on Evolent Health from $12.00 to $6.00 and set an "outperform" rating for the company in a research report on Monday, March 2nd. Finally, BTIG Research cut their target price on Evolent Health from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, February 25th.

Institutional Trading of Evolent Health

Several institutional investors have recently made changes to their positions in EVH. Durable Capital Partners LP purchased a new stake in shares of Evolent Health during the second quarter worth about $72,326,000. Rubicon Founders LLC bought a new stake in Evolent Health in the 3rd quarter worth approximately $49,204,000. 8 Knots Management LLC bought a new stake in Evolent Health in the 2nd quarter worth approximately $32,802,000. Eventide Asset Management LLC increased its stake in Evolent Health by 54.0% in the 3rd quarter. Eventide Asset Management LLC now owns 6,292,511 shares of the technology company's stock worth $53,246,000 after acquiring an additional 2,205,659 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Evolent Health by 162.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company's stock worth $26,861,000 after acquiring an additional 1,754,520 shares during the last quarter.

Evolent Health Stock Performance

Shares of EVH opened at $2.51 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 2.34. The business has a 50-day simple moving average of $2.75 and a two-hundred day simple moving average of $4.29. The stock has a market cap of $280.22 million, a price-to-earnings ratio of -0.49 and a beta of 0.37. Evolent Health has a 52 week low of $2.10 and a 52 week high of $12.06.

Evolent Health (NYSE:EVH - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. Evolent Health had a positive return on equity of 1.49% and a negative net margin of 28.49%.The business had revenue of $468.72 million during the quarter, compared to analysts' expectations of $468.48 million. During the same quarter in the prior year, the business posted ($0.02) earnings per share. The business's quarterly revenue was down 27.5% on a year-over-year basis. On average, analysts expect that Evolent Health will post 0.08 EPS for the current year.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company's core offerings include care management solutions, population health analytics and clinical advisory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.